Biophage invited to London 10th Annual Superbugs & Superdrugs conference



    Biophage also announces resignation of a member of its Board

    MONTREAL, March 14 /CNW Telbec/ - (TSX.V: BUG) - Biophage Pharma today
announced that it will present its most recent developments in the management
of MRSA contamination in a hospital environment at the SMi's 10th Annual
conference entitled "Superbugs & Superdrugs; a focus on antibacterials"
(London, England, April 9 and 10, 2008). Biophage will present a platform
presentation and host a half-day pre-conference workshop entitled "Phage
Theranostics: A safe and integrated approach for the management of superbugs".
    "This international conference represents a great opportunity to place
Biophage technology solutions in the heart of the superbugs issue. The
presentation at the conference, the workshop and the subsequent private
meetings will provide exposure of Biophage products to both public and private
organizations as well as private companies that are striving to find novel
technologies for the control of hospital and community acquired MRSA
infections." commented Dr. Rosemonde Mandeville, President and CEO of Biophage
Pharma.
    Biophage also announced that Mrs. Winnie Fok has resigned as member of
the Company board of directors effective March 13, 2008. "The Board of
directors and Management wish to thank Mrs. Winnie Fok for her contribution to
Biophage over the past few years and wish her the best of luck in her future
career." concluded Dr Mandeville.

    About Biophage Pharma Inc.

    Biophage is a Canadian biotechnology company focused on the development
of innovative phage-based products and technologies for the detection,
prevention and control of bacterial infections. Biophage also operates the
Immunotox Labs division, which provides services in Immunogenicity and
Immunotoxicity, screening for Beryllium sensitization (the BeLPT test) and
exclusive MELISA(R) for the detection of sensitization to more than 200
different allergens including metals, penicillin, gluten, pollens and more
recently Lyme disease (Boreliosis).
    (www.biophagepharma.net; www.immunotoxlabs.com)

    The TSX Venture Exchange does not accept responsibility for the adequacy
    or accuracy of this release.




For further information:

For further information: Rosemonde Mandeville, M.B., Ch.B., PhD.
President and CEO, Biophage Pharma Inc., (514) 496-1488,
rosemonde.mandeville@biophagepharma.net; Louis Guindon, Chief Financial
Officer, Biophage Pharma Inc., (514) 496-3230,
louis.guindon@biophagepharma.net

Organization Profile

BIOPHAGE PHARMA, INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890